Coloplast prepares big study of main asset from million-dollar acquisition

After the acquisition of Nine Continents Medical, Coloplast is getting ready to try out the US-based urology firm's main asset against over-active bladder disorder (OAB) in a big clinical trial in the US. The company is expecting to release the results as soon as next year, and hopes for a potential launch in 2024-2025.
Photo: Coloplast / PR
Photo: Coloplast / PR

Coloplast is taking its first step into a new segment of the urology area. The medtech company has just made the final preparations for an extensive clinical study with the company's solution, a "tibial nerve stimulator," for over-active bladder disorder (OAB), the company reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading